Sort
48,018 grants matching “immunotherapy”
Understanding Early Drivers and Therapeutic Targets for Severe Forms of Arrhythmogenic Cardiomyopathy
$727,710Farah Sheikh · University Of California, San Diego · R01 · FY2025 · HL
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of
$727,574Anne Searls De Groot · Epivax, Inc. · R44 · FY2013 · DK
T cells in the aging brain
$727,495Anne Brunet · Stanford University · R01 · FY2023 · AG
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection
$727,487M. Javad Aman · Integrated Biotherapeutics, Inc. · R01 · FY2022 · AI
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
$727,344Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
$727,344Prasad S. Adusumilli · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
Molecular Pharmacology of NKT Cell Agonists
$727,292Luc Teyton · Scripps Research Institute, The · R01 · FY2017 · AI
Molecular Pharmacology of NKT Cell Agonists
$727,292Luc Teyton · Scripps Research Institute, The · R01 · FY2016 · AI
Translating cellular immunotherapies for autoimmunity to canine clinical trials
$727,277Aimee S Payne · University Of Pennsylvania · R01 · FY2018 · AR
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$727,275Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2023 · CA
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$727,272Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2021 · CA
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$727,264Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2025 · CA
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
$727,224Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Project 2: Characterizing humoral responses to SARS-CoV-2, and the immunological and biological effects of plasma therapy for severe Covid-19
$727,058Luther A Bartelt · Univ Of North Carolina Chapel Hill · U54 · FY2020 · CA
Targeting Protein Arginine Methyltransferases to Eradicate Acute Myeloid Leukemia
$727,057Ling Li · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Career Development in Pediatric and Medical Oncology
$726,905Soheil Meshinchi · Fred Hutchinson Cancer Center · K12 · FY2022 · CA
Building on the success of the adoptive immunotherapy of cancer
$726,880Steven Rosenberg · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$726,788Meghan E. Sise · Massachusetts General Hospital · R01 · FY2022 · DK
T cells in the aging brain
$726,768Anne Brunet · Stanford University · R01 · FY2024 · AG
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
$726,766Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2018 · CA
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$726,628Meghan E. Sise · Massachusetts General Hospital · R01 · FY2023 · DK
COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANS
$726,447Shabaana A. Khader · Washington University · R01 · FY2018 · AI
Leveraging fructose transport to create a privileged substrate to selectively fuel T cells
$726,151Kayvan R Keshari · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Functional Biology Of T Cells
$726,148Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
BREAST CANCER IMMUNOTHERAPY WITH ANTI-TIM-3
$726,110H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. · · FY2020 · Defense Health Agency